[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Michael Geffner Biography and Net Worth

Chief Medical Officer of Immunovant

Prior to joining Immunovant, Dr. Geffner was the Chief Medical Officer and head of Product Development for BlueSphere Bio (BSB), an Immuno-Oncology company focused on developing adoptive T-cell therapeutics. Before his role at BSB, he led Hematology Clinical Development for the danicopan development program and was the Head of Global Medical Affairs for Achillion Pharmaceuticals (now Astra Zeneca). Prior to Achillion, he spent 15 years in various senior leadership positions at Schering-Plough/Merck across Clinical Development, Clinical Operations, and Medical Affairs. His other prior roles include, Head of the Anti-infectives/hospital and specialty care Medical Affairs teams, US Medical Affairs integration lead, and Clinical Development Leader.

Dr. Geffner has dual board certification from the American Board of Pediatrics and The American Board of Psychiatry and Neurology, with special competency in Child Neurology. He is a Graduate of Albany Medical College and holds an MBA from Fairleigh Dickinson University

What is Michael Geffner's net worth?: The estimated net worth of Michael Geffner is at least $3.60 million as of July 24th, 2024. Dr. Geffner owns 138,160 shares of Immunovant stock worth more than $3,599,068 as of November 21st. This net worth estimate does not reflect any other investments that Dr. Geffner may own. Learn More about Michael Geffner's net worth.
How do I contact Michael Geffner?: The corporate mailing address for Dr. Geffner and other Immunovant executives is 320 WEST 37TH STREET, NEW YORK NY, 10018. Immunovant can also be reached via phone at 917-580-3099 and via email at [email protected]. Learn More on Michael Geffner's contact information.
Has Michael Geffner been buying or selling shares of Immunovant?: Michael Geffner has not been actively trading shares of Immunovant during the last ninety days. Most recently, Michael Geffner sold 3,456 shares of the business's stock in a transaction on Wednesday, July 24th. The shares were sold at an average price of $27.76, for a transaction totalling $95,938.56. Following the completion of the sale, the insider now directly owns 138,160 shares of the company's stock, valued at $3,835,321.60. Learn More on Michael Geffner's trading history.
Who are Immunovant's active insiders?: Immunovant's insider roster includes Peter . (), Eva Barnett (CFO), Julia Butchko (Insider), Michael Geffner (Chief Medical Officer), Douglas Hughes (Director), Mark Levine (Chief Legal Officer and Corporate Secretary), William Macias (Insider), George Migausky (Director), Atul Pande (Director), Peter Salzmann (CEO), Jay Stout (CTO), and Frank Torti (Director). Learn More on Immunovant's active insiders.
Are insiders buying or selling shares of Immunovant?: During the last twelve months, insiders at the sold shares 36 times. They sold a total of 204,388 shares worth more than $6,214,884.80. The most recent insider tranaction occured on October, 23rd when insider Mark S Levine sold 4,361 shares worth more than $128,780.33. Insiders at Immunovant own 5.9% of the company. Learn More about insider trades at Immunovant.
Information on this page was last updated on 10/23/2024.

Michael Geffner Insider Trading History at Immunovant

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/24/2024	Sell	3,456	$27.76	$95,938.56	138,160
4/24/2024	Sell	3,261	$28.90	$94,242.90	141,616

Michael Geffner Buying and Selling Activity at Immunovant

Immunovant Company Overview

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Today's Range

Now: $26.05

$25.99

$26.47

50 Day Range

MA: $29.18

$25.22

$31.42

2 Week Range

Now: $26.05

$24.61

$45.58

Volume

65,588 shs

Average Volume

1,078,137 shs

Market Capitalization

$3.82 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.66